207 related articles for article (PubMed ID: 10760047)
21. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
22. Reverse transcriptase activity of hepatitis B virus (HBV) DNA polymerase within core capsid: interaction with deoxynucleoside triphosphates and anti-HBV L-deoxynucleoside analog triphosphates.
Lam W; Li Y; Liou JY; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Feb; 65(2):400-6. PubMed ID: 14742682
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
[TBL] [Abstract][Full Text] [Related]
24. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.
Colledge D; Civitico G; Locarnini S; Shaw T
Antimicrob Agents Chemother; 2000 Mar; 44(3):551-60. PubMed ID: 10681317
[TBL] [Abstract][Full Text] [Related]
25. Evolutionary trends of resistance mutational patterns of HBV reverse transcriptase over years (2002-2012) of different treatment regimens: The legacy of lamivudine/adefovir combination treatment.
Vincenti D; Piselli P; Solmone M; D'Offizi G; Capobianchi MR; Menzo S
Antiviral Res; 2017 Jul; 143():62-68. PubMed ID: 28322924
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents.
Qi X; Xiong S; Yang H; Miller M; Delaney WE
Antivir Ther; 2007; 12(3):355-62. PubMed ID: 17591025
[TBL] [Abstract][Full Text] [Related]
27. Screening and identification of a novel adefovir dipivoxil resistance associated mutation, rtN236V, of HBV from a large cohort of HBV-infected patients.
Liu Y; Liu W; Li X; Xu Z; Wang X; Li C; Chen L; Xin S; Xu D
Antivir Ther; 2014; 19(6):551-8. PubMed ID: 24710668
[TBL] [Abstract][Full Text] [Related]
28. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.
Walters KA; Tipples GA; Allen MI; Condreay LD; Addison WR; Tyrrell L
Antimicrob Agents Chemother; 2003 Jun; 47(6):1936-42. PubMed ID: 12760870
[TBL] [Abstract][Full Text] [Related]
29. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.
Delaney WE; Locarnini S; Shaw T
Antivir Chem Chemother; 2001 Jan; 12(1):1-35. PubMed ID: 11437320
[TBL] [Abstract][Full Text] [Related]
30. Doctor to patient transmission of hepatitis B virus: implications of HBV DNA levels and potential new solutions.
Buster EH; van der Eijk AA; Schalm SW
Antiviral Res; 2003 Oct; 60(2):79-85. PubMed ID: 14638402
[TBL] [Abstract][Full Text] [Related]
31. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Núñez M; Pérez-Olmeda M; Díaz B; Ríos P; González-Lahoz J; Soriano V
AIDS; 2002 Nov; 16(17):2352-4. PubMed ID: 12441815
[TBL] [Abstract][Full Text] [Related]
32. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside/nucleotide inhibitors.
Niu C; Bao H; Tolstykh T; Micolochick Steuer HM; Murakami E; Korba B; Furman PA
Antivir Ther; 2010; 15(3):401-12. PubMed ID: 20516559
[TBL] [Abstract][Full Text] [Related]
34. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
Ladner SK; Miller TJ; Otto MJ; King RW
Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
[TBL] [Abstract][Full Text] [Related]
35. Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues.
Zhu Y; Curtis M; Qi X; Miller MD; Borroto-Esoda K
Antivir Chem Chemother; 2009; 19(4):165-76. PubMed ID: 19374144
[TBL] [Abstract][Full Text] [Related]
36. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.
Amini-Bavil-Olyaee S; Herbers U; Luedde T; Trautwein C; Tacke F
J Viral Hepat; 2011 Nov; 18(11):804-14. PubMed ID: 20887378
[TBL] [Abstract][Full Text] [Related]
37. In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.
Jacquard AC; Brunelle MN; Pichoud C; Durantel D; Carrouée-Durantel S; Trepo C; Zoulim F
Antimicrob Agents Chemother; 2006 Mar; 50(3):955-61. PubMed ID: 16495257
[TBL] [Abstract][Full Text] [Related]
38. Increased occurrence of mutant rtI233V of HBV in patients receiving adefovir therapy.
Liu Y; Xin S; Ye X; Chen R; Xu Z; Li X; Ye H; Cheng S; Xu D
Antivir Ther; 2016; 21(1):9-16. PubMed ID: 26079809
[TBL] [Abstract][Full Text] [Related]
39. The acyclic nucleoside phosphonate analogues, adefovir, tenofovir and PMEDAP, efficiently eliminate banana streak virus from banana (Musa spp.).
Helliot B; Panis B; Frison E; De Clercq E; Swennen R; Lepoivre P; Neyts J
Antiviral Res; 2003 Jul; 59(2):121-6. PubMed ID: 12895695
[TBL] [Abstract][Full Text] [Related]
40. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
Ono SK; Kato N; Shiratori Y; Kato J; Goto T; Schinazi RF; Carrilho FJ; Omata M
J Clin Invest; 2001 Feb; 107(4):449-55. PubMed ID: 11181644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
